甲状腺癌的分子靶向治疗进展  

Progress in molecular targeted therapy for thyroid carcinoma

作　　者：冀叶[1] 马静[1] 李晓江[1] 

机构地区：[1]昆明医学院第三附属医院(云南省肿瘤医院)头颈外科,云南省头颈肿瘤研究中心,昆明650118

出　　处：《肿瘤》2011年第7期671-674,共4页Tumor

摘　　要：甲状腺癌的治疗方法主要以手术为主,但对于转移性的、侵袭性的和晚期的甲状腺癌患者来说,手术效果有限,而且碘放射治疗和化疗对这些恶性程度较高的肿瘤治疗效果往往不太理想,因此分子靶向治疗的出现则为这些患者带来了新的希望。本文将从甲状腺癌发病的分子机制,分子靶向治疗药物的作用机制、治疗效果和不良反应等方面作一综述。The treatment for thyroid cancer is mainly based on surgery. However, for the patients with metastatic, invasive and advanced thyroid cancer, the therapeutic efficacy of surgical operation is limited. Meanwhile, the radioactive iodine therapy and chemotherapy for high-grade thyroid cancer exert no substantial effects. The development of molecular targeted therapy brings new hopes for these patients. This article reviews the molecular pathogenesis of thyroid cancer, the mechanism of action of molecular targeted drugs and the therapeutic effects and adverse reactions of these targeted drugs.

关 键 词：甲状腺肿瘤 蛋白激酶抑制剂类 抗肿瘤联合化疗方案 

分 类 号：R736.1[医药卫生—肿瘤]